KalVista Pharmaceuticals (KALV) Cash & Equivalents (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Cash & Equivalents of $124.3 million in Q3 2025, down 5.55% quarter-over-quarter from $131.6 million in Q2 2025, and up 290.3% year-over-year from $31.8 million in Q3 2024.
KalVista Pharmaceuticals' Cash & Equivalents history runs 12 years deep, the most recent figure standing at $124.3 million for Q3 2025.
- In Q3 2025, Cash & Equivalents rose 290.3% year-over-year to $124.3 million; the TTM figure through Jul 2025 stood at $124.3 million (up 290.3% YoY), while the FY2025 annual figure was $131.6 million, up 314.03% from the prior year.
- Cash & Equivalents came in at $124.3 million for Q3 2025 at KalVista Pharmaceuticals, down from $131.6 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $182.3 million in Q4 2024 to a low of $17.7 million in Q1 2021.
- A 5-year average of $59.5 million and a median of $46.5 million in 2021 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents plunged 72.89% in 2024 and surged 314.03% in 2025, its largest moves.
- KalVista Pharmaceuticals' Cash & Equivalents stood at $46.5 million in 2021, then slipped by 17.01% to $38.6 million in 2022, then jumped by 49.45% to $57.7 million in 2023, then soared by 216.18% to $182.3 million in 2024, then plunged by 31.82% to $124.3 million in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $124.3 million, $131.6 million, and $182.3 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 124.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 124.30 Mn |
| Apr 30, 2025 | 131.62 Mn |
| Dec 31, 2024 | 182.33 Mn |
| Oct 31, 2024 | 41.58 Mn |
| Jul 31, 2024 | 31.85 Mn |
| Apr 30, 2024 | 31.79 Mn |
| Jan 31, 2024 | 23.06 Mn |
| Oct 31, 2023 | 57.67 Mn |
| Jul 31, 2023 | 49.41 Mn |
| Apr 30, 2023 | 56.24 Mn |
| Jan 31, 2023 | 85.05 Mn |
| Oct 31, 2022 | 38.59 Mn |
| Jul 31, 2022 | 37.86 Mn |
| Apr 30, 2022 | 30.73 Mn |
| Jan 31, 2022 | 45.58 Mn |
| Oct 31, 2021 | 46.49 Mn |
| Jul 31, 2021 | 48.34 Mn |
| Apr 30, 2021 | 50.59 Mn |
| Jan 31, 2021 | 17.73 Mn |
| Oct 31, 2020 | 16.17 Mn |
| Jul 31, 2020 | 18.01 Mn |
| Apr 30, 2020 | 15.79 Mn |
| Jan 31, 2020 | 18.62 Mn |
| Oct 31, 2019 | 21.72 Mn |
| Jul 31, 2019 | 30.11 Mn |
| Apr 30, 2019 | 32.01 Mn |
| Jan 31, 2019 | 56.35 Mn |
| Oct 31, 2018 | 121.12 Mn |
| Jul 31, 2018 | 48.07 Mn |
| Apr 30, 2018 | 51.06 Mn |
| Jan 31, 2018 | 58.68 Mn |
| Oct 31, 2017 | 28.13 Mn |
| Jul 31, 2017 | 26.46 Mn |
| Apr 30, 2017 | 30.95 Mn |
| Jan 31, 2017 | 33.50 Mn |
| Oct 31, 2016 | 10.69 Mn |
| Jul 31, 2016 | 15.63 Mn |
| Mar 31, 2016 | 48.59 Mn |
| Dec 31, 2015 | 53.72 Mn |
| Sep 30, 2015 | 59.88 Mn |
| Jun 30, 2015 | 65.38 Mn |
| Mar 31, 2015 | 3.18 Mn |
| Dec 31, 2014 | 3.90 Mn |
| Sep 30, 2014 | 9.33 Mn |
| Jun 30, 2014 | 7.18 Mn |
| Mar 31, 2014 | 9.28 Mn |